2,4-thiazolidinedione has been researched along with Disease Models, Animal in 25 studies
thiazolidine-2,4-dione: structure in first source
1,3-thiazolidine-2,4-dione : A thiazolidenedione carrying oxo substituents at positions 2 and 4.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the present study, we demonstrated that GPU-4, 5-arylidene-2,4-thiazolidinedione derivative, demonstrates anti-angiogenic activity regarding human retinal microvascular endothelial cells (HRMECs) and retinal neovascularization in a mouse model of retinopathy of prematurity." | 3.77 | An arylidene-thiazolidinedione derivative, GPU-4, without PPARγ activation, reduces retinal neovascularization. ( Hara, H; Hayashi, K; Kakuta, H; Murase, T; Nagasawa, H; Nakamura, S; Shimazawa, M; Takizawa, H; Tsuruma, K, 2011) |
| "2% troglitazone was administered from 1 month to 7 months of age in WBN/Kob rats with spontaneous chronic pancreatitis." | 3.71 | Thiazolidinedione derivatives as novel therapeutic agents to prevent the development of chronic pancreatitis. ( Fujiwara, T; Hayashi, N; Horikoshi, H; Kobayashi, M; Shimizu, K; Shiratori, K, 2002) |
| "Obesity is frequently associated with excess caloric fat dietary intake, especially in the form of fatty acids." | 2.41 | Pharmacological treatment of insulin resistance in obesity. ( Camejo, G; Ljung, B; Oakes, N, 2001) |
| "The development of liver fibrosis was reduced in rats receiving TGZ, as indicated by significant decreases of procollagen type I gene expression and liver hydroxy-proline levels." | 1.33 | Thiazolidinedione treatment inhibits bile duct proliferation and fibrosis in a rat model of chronic cholestasis. ( DeFranco, R; Efsen, E; Lottini, B; Marra, F; Novo, E; Parola, M; Pastacaldi, S; Pinzani, M; Robino, G; Spirli, C; Strazzabosco, M; Vercelli, A; Zamara, E, 2005) |
| "Rosiglitazone treatment increased the triglyceride content of the steatotic livers of A-ZIP/F-1 and ob/ob mice, but not the "lean" livers of fat-transplanted A-ZIP/F-1 mice." | 1.31 | Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. ( Arioglu, E; Chao, L; Gavrilova, O; Marcus-Samuels, B; Mason, MM; Moitra, J; Reitman, ML; Vinson, C, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (68.00) | 29.6817 |
| 2010's | 7 (28.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lane, SL | 1 |
| Doyle, AS | 1 |
| Bales, ES | 1 |
| Houck, JA | 1 |
| Lorca, RA | 1 |
| Moore, LG | 1 |
| Julian, CG | 1 |
| Naim, MJ | 1 |
| Alam, MJ | 1 |
| Nawaz, F | 1 |
| Naidu, VGM | 1 |
| Aaghaz, S | 1 |
| Sahu, M | 1 |
| Siddiqui, N | 1 |
| Alam, O | 1 |
| Yasmin, S | 1 |
| Capone, F | 1 |
| Laghezza, A | 1 |
| Piaz, FD | 1 |
| Loiodice, F | 1 |
| Vijayan, V | 1 |
| Devadasan, V | 1 |
| Mondal, SK | 1 |
| Atlı, Ö | 1 |
| Baysal, M | 1 |
| Pattnaik, AK | 1 |
| Jayaprakash, V | 1 |
| Lavecchia, A | 1 |
| Ferreira, AE | 1 |
| Sisti, F | 1 |
| Sônego, F | 1 |
| Wang, S | 1 |
| Filgueiras, LR | 1 |
| Brandt, S | 1 |
| Serezani, AP | 1 |
| Du, H | 1 |
| Cunha, FQ | 1 |
| Alves-Filho, JC | 1 |
| Serezani, CH | 1 |
| Nakamura, S | 1 |
| Hayashi, K | 1 |
| Takizawa, H | 1 |
| Murase, T | 1 |
| Tsuruma, K | 1 |
| Shimazawa, M | 1 |
| Kakuta, H | 1 |
| Nagasawa, H | 1 |
| Hara, H | 1 |
| Choi, JH | 1 |
| Banks, AS | 1 |
| Kamenecka, TM | 1 |
| Busby, SA | 1 |
| Chalmers, MJ | 1 |
| Kumar, N | 1 |
| Kuruvilla, DS | 1 |
| Shin, Y | 1 |
| He, Y | 1 |
| Bruning, JB | 1 |
| Marciano, DP | 1 |
| Cameron, MD | 1 |
| Laznik, D | 1 |
| Jurczak, MJ | 1 |
| Schürer, SC | 1 |
| Vidović, D | 1 |
| Shulman, GI | 1 |
| Spiegelman, BM | 1 |
| Griffin, PR | 1 |
| Chiang, MC | 1 |
| Chern, Y | 1 |
| Huang, RN | 1 |
| Kasono, K | 1 |
| Nishida, J | 1 |
| Tamemoto, H | 1 |
| Fudaka, K | 1 |
| Namai, K | 1 |
| Kajio, H | 1 |
| Masatoshi, K | 1 |
| Kanazawa, Y | 1 |
| Kawakami, M | 1 |
| Chakrabarti, R | 1 |
| Vikramadithyan, RK | 1 |
| Kumar, MP | 1 |
| Kumar, SK | 1 |
| Mamidi, NV | 1 |
| Misra, P | 1 |
| Suresh, J | 1 |
| Hiriyan, J | 1 |
| Rao, CS | 1 |
| Rajagopalan, R | 1 |
| Vázquez, M | 1 |
| Silvestre, JS | 1 |
| Prous, JR | 1 |
| Koyama, H | 1 |
| Boueres, JK | 1 |
| Han, W | 1 |
| Metzger, EJ | 1 |
| Bergman, JP | 1 |
| Gratale, DF | 1 |
| Miller, DJ | 1 |
| Tolman, RL | 1 |
| MacNaul, KL | 1 |
| Berger, JP | 1 |
| Doebber, TW | 1 |
| Leung, K | 1 |
| Moller, DE | 1 |
| Heck, JV | 1 |
| Sahoo, SP | 1 |
| Cariou, B | 1 |
| Capitaine, N | 1 |
| Le Marcis, V | 1 |
| Vega, N | 1 |
| Béréziat, V | 1 |
| Kergoat, M | 1 |
| Laville, M | 1 |
| Girard, J | 1 |
| Vidal, H | 1 |
| Burnol, AF | 1 |
| Kim, BY | 1 |
| Ahn, JB | 1 |
| Lee, HW | 1 |
| Kang, SK | 1 |
| Lee, JH | 1 |
| Shin, JS | 1 |
| Ahn, SK | 1 |
| Hong, CI | 1 |
| Yoon, SS | 1 |
| Kim, H | 1 |
| Haluzik, M | 1 |
| Gavrilova, O | 2 |
| Yakar, S | 1 |
| Portas, J | 1 |
| Sun, H | 1 |
| Pajvani, UB | 1 |
| Scherer, PE | 1 |
| LeRoith, D | 1 |
| Marra, F | 1 |
| DeFranco, R | 1 |
| Robino, G | 1 |
| Novo, E | 1 |
| Efsen, E | 1 |
| Pastacaldi, S | 1 |
| Zamara, E | 1 |
| Vercelli, A | 1 |
| Lottini, B | 1 |
| Spirli, C | 1 |
| Strazzabosco, M | 1 |
| Pinzani, M | 1 |
| Parola, M | 1 |
| Takaki, K | 1 |
| Mitsuyama, K | 1 |
| Tsuruta, O | 1 |
| Toyonaga, A | 1 |
| Sata, M | 1 |
| Ali, AM | 1 |
| Saber, GE | 1 |
| Mahfouz, NM | 1 |
| El-Gendy, MA | 1 |
| Radwan, AA | 1 |
| Hamid, MA | 1 |
| Chao, L | 1 |
| Marcus-Samuels, B | 1 |
| Mason, MM | 1 |
| Moitra, J | 1 |
| Vinson, C | 1 |
| Arioglu, E | 1 |
| Reitman, ML | 1 |
| Hu, B | 1 |
| Ellingboe, J | 1 |
| Gunawan, I | 1 |
| Han, S | 1 |
| Largis, E | 1 |
| Li, Z | 1 |
| Malamas, M | 1 |
| Mulvey, R | 1 |
| Oliphant, A | 1 |
| Sum, FW | 1 |
| Tillett, J | 1 |
| Wong, V | 1 |
| Boelsterli, UA | 1 |
| Bedoucha, M | 1 |
| Camejo, G | 1 |
| Ljung, B | 1 |
| Oakes, N | 1 |
| Shimizu, K | 1 |
| Shiratori, K | 1 |
| Hayashi, N | 1 |
| Kobayashi, M | 1 |
| Fujiwara, T | 1 |
| Horikoshi, H | 1 |
| Picard, F | 1 |
| Auwerx, J | 1 |
| Nazreen, S | 1 |
| Alam, MS | 1 |
| Hamid, H | 1 |
| Yar, MS | 1 |
| Dhulap, A | 1 |
| Alam, P | 1 |
| Pasha, MA | 1 |
| Bano, S | 1 |
| Alam, MM | 1 |
| Haider, S | 1 |
| Kharbanda, C | 1 |
| Ali, Y | 1 |
| Pillai, KK | 1 |
| Yaturu, S | 1 |
5 reviews available for 2,4-thiazolidinedione and Disease Models, Animal
| Article | Year |
|---|---|
Experimental approaches to study PPAR gamma agonists as antidiabetic drugs.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Hypoglycemic Agents; Receptors, | 2002 |
Toxicological consequences of altered peroxisome proliferator-activated receptor gamma (PPARgamma) expression in the liver: insights from models of obesity and type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Liver; Mice; Obesity; Receptors, Cytopla | 2002 |
Pharmacological treatment of insulin resistance in obesity.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Hypoglycemic Agents; Insulin Res | 2001 |
PPAR(gamma) and glucose homeostasis.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Gene Expression Regulatio | 2002 |
Diabetes and skeletal health.
Topics: Adipocytes; Animals; Bone and Bones; Bone Density; Diabetes Complications; Diabetes Mellitus; Diabet | 2009 |
20 other studies available for 2,4-thiazolidinedione and Disease Models, Animal
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor gamma blunts endothelin-1-mediated contraction of the uterine artery in a murine model of high-altitude pregnancy.
Topics: Animals; Disease Models, Animal; Endothelin-1; Female; Fetal Growth Retardation; Hypoxia; Immunohist | 2020 |
Synthesis, molecular docking and anti-diabetic evaluation of 2,4-thiazolidinedione based amide derivatives.
Topics: Amides; Animals; Diabetes Mellitus, Experimental; Disease Models, Animal; Female; Hypoglycemic Agent | 2017 |
Novel Benzylidene Thiazolidinedione Derivatives as Partial PPARγ Agonists and their Antidiabetic Effects on Type 2 Diabetes.
Topics: Animals; Benzylidene Compounds; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease | 2017 |
PPAR-γ/IL-10 axis inhibits MyD88 expression and ameliorates murine polymicrobial sepsis.
Topics: Animals; Disease Models, Animal; Female; Gene Expression Regulation; Hypoglycemic Agents; Interleuki | 2014 |
An arylidene-thiazolidinedione derivative, GPU-4, without PPARγ activation, reduces retinal neovascularization.
Topics: Angiogenesis Inhibitors; Animals; Benzylidene Compounds; Cells, Cultured; Disease Models, Animal; En | 2011 |
Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue, White; Animals; Biphenyl Compounds; Body Fluids; Chloroceb | 2011 |
PPARgamma rescue of the mitochondrial dysfunction in Huntington's disease.
Topics: Animals; Cerebral Cortex; Disease Models, Animal; Down-Regulation; Energy Metabolism; Huntington Dis | 2012 |
Thiazolidinediones increase the number of platelets in immune thrombocytopenic purpura mice via inhibition of phagocytic activity of the reticulo-endothelial system.
Topics: Animals; Antibody-Dependent Cell Cytotoxicity; Autoantibodies; Blood Platelets; COS Cells; Disease M | 2002 |
PMT13, a pyrimidone analogue of thiazolidinedione improves insulin resistance-associated disorders in animal models of type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Hypoglycemic Agents; Insulin Resistance; | 2002 |
5-Aryl thiazolidine-2,4-diones as selective PPARgamma agonists.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Hypoglycemic Agents; Inhi | 2003 |
Increased adipose tissue expression of Grb14 in several models of insulin resistance.
Topics: 3T3 Cells; Adaptor Proteins, Signal Transducing; Adipocytes; Adipose Tissue; Animals; Carrier Protei | 2004 |
Synthesis and biological activity of novel substituted pyridines and purines containing 2,4-thiazolidinedione.
Topics: 3T3-L1 Cells; Animals; Blood Glucose; Cell Division; Cells, Cultured; Diabetes Mellitus, Experimenta | 2004 |
Thiazolidinediones improve insulin sensitivity in adipose tissue and reduce the hyperlipidaemia without affecting the hyperglycaemia in a transgenic model of type 2 diabetes.
Topics: Adipose Tissue; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Hyperglyc | 2004 |
Thiazolidinedione treatment inhibits bile duct proliferation and fibrosis in a rat model of chronic cholestasis.
Topics: Animals; Bile Ducts; Cell Division; Cholestasis; Chronic Disease; Disease Models, Animal; Hypoglycem | 2005 |
Attenuation of experimental colonic injury by thiazolidinedione agents.
Topics: Animals; Colon; Colonic Diseases; Cytokines; Disease Models, Animal; Female; Hypoglycemic Agents; In | 2006 |
Synthesis and three-dimensional qualitative structure selectivity relationship of 3,5-disubstituted-2,4-thiazolidinedione derivatives as COX2 inhibitors.
Topics: Animals; Carrageenan; Catalytic Domain; Computer Simulation; Crystallography, X-Ray; Cyclooxygenase | 2007 |
Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones.
Topics: Adipose Tissue; Animals; Blood Glucose; Chromans; Diabetes Mellitus, Lipoatrophic; Disease Models, A | 2000 |
2,4-Thiazolidinediones as potent and selective human beta3 agonists.
Topics: Adrenergic beta-3 Receptor Agonists; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Hum | 2001 |
Thiazolidinedione derivatives as novel therapeutic agents to prevent the development of chronic pancreatitis.
Topics: Amylases; Animals; Antineoplastic Agents; Blood Glucose; Chromans; Chronic Disease; Disease Models, | 2002 |
Thiazolidine-2,4-diones derivatives as PPAR-γ agonists: synthesis, molecular docking, in vitro and in vivo antidiabetic activity with hepatotoxicity risk evaluation and effect on PPAR-γ gene expression.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Disease Models, Animal; Gene Expression Reg | 2014 |